FDA, Merck Clash Over Value Of Subjective Insomnia Endpoints
Executive Summary
Merck favors the subjective study endpoints, perhaps with an eye toward potential marketing challenges, and the Rozerem experience could haunt Merck’s dreams.
You may also be interested in...
Suvorexant’s Strike One: Higher Doses Out, More Low Dose Studies In
Merck’s “complete response” for insomnia drug suvorexant indicates FDA wants drug doses the company has said are ineffective.
If Sponsors Don’t Ask, FDA Can’t Always Deliver: Merck’s Suvorexant Dosing Debacle
Sponsors may need to be more proactive in reaching out to the agency if they want to avoid the kind of dosing confusion currently facing Merck’s insomnia drug suvorexant, FDA indicates.
Takeda Rozerem Clinical Significance Debated In FDA Review
The "curious" failure of subjective secondary endpoints to agree with the efficacy of Takeda’s Rozerem on objective sleep measures contributed to a debate at FDA over the clinical significance of the insomnia therapy.